Retina/Vitreous News

CHICAGO — In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Diana Do, MD, discusses the PHOTON extension study, which examined the effect of Eylea HD in patients with diabetic macular edema.

NEW YORK — In this Healio Video Perspective from OSN New York, Sanjay Nayak, MBBS, PhD, of Ocular Therapeutix discusses Axpaxli for the treatment of retinal vascular diseases.

Patients with type 2 diabetes recently diagnosed with diabetic retinopathy had a significantly reduced concentration of progranulin in their tears compared with control patients, according to prospective study results.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Michel Dahan, CEO of Alkeus Pharmaceuticals discusses ALK-001, the company’s oral therapy for the treatment of Stargardt’s disease and age-related macular degeneration.

BARCELONA, Spain – In this Healio Video Perspective from the Euretina congress, David Wong, MD, shares his thoughts on the advantages of new drugs for retinal conditions including age-related macular degeneration.

A novel primary care optometry-based diabetic retinopathy service served as an efficient, safe alternative to hospital services and offered advantages over virtual clinics, according to a study conducted in the U.K. and published in Eye.

NEW YORK — In this Healio Video Perspective from OSN New York Retina, Lejla Vajzovic, MD, FASRS, of Duke Eye Center in Durham, North Carolina, discusses the adoption of therapies for the treatment of geographic atrophy.

CHICAGO — In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Carl D. Regillo, MD, FACS, of Wills Eye Hospital, shares study results from the phase 2 DAVIO 2 trial.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Peter K. Kaiser, MD, of Ocular Therapeutix, discusses the company’s shift to a retina-focused program.

BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Jordi Monés, MD, PhD, discusses an investigational optogenetic therapy for geographic atrophy.